Recommended Products
biological source
mouse
Quality Level
100
500
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
MRQ-1, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (254M-14)
vial of 0.5 mL concentrate (254M-15)
bottle of 1.0 mL predilute (254M-17)
vial of 1.0 mL concentrate (254M-16)
bottle of 7.0 mL predilute (254M-18)
manufacturer/tradename
Cell Marque™
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
isotype
IgG2b
control
pnet
shipped in
wet ice
storage temp.
2-8°C
visualization
nuclear
Gene Information
human ... FLI1(2313)
Related Categories
General description
Ewing sarcoma/peripheral primitive neuroectodermal tumor (ES/PNET) is a rare primary tumor of the bone/soft tissue that resembles other undifferentiated tumors. The differential diagnosis of undifferentiated tumors of the soft tissue includes blastemal Wilms tumor, rhabdoid tumor, neuroblastoma, lymphoma, clear cell sarcoma, small cell carcinoma, synovial sarcoma (SS), neuroblastoma, desmoplastic small round cell tumor (DSRCT), and ES/PNET. It is important to correctly classify these tumors for appropriate treatment. The most common primitive renal tumor, Wilms tumor, responds well to a standard regimen of multiagent chemotherapy, whereas renal ES/PNET tends to be a high-stage, aggressive neoplasm that requires more extensive therapy .
The FLI-1 gene and FLI-1 protein are best known for their critical role in the pathogenesis of ES/PNET. More than 85% of ES/PNET are characterized by the translocation t(11;22)(q24;q12) that results in the fusion of the ews gene on chromosome 22 to the FLI-1 gene on chromosome 11. FLI-1 is a member of the ETS (erythroblastosis virus-associated transforming sequences) family of DNA-binding transcription factors and is involved in cellular proliferation and tumorigenesis. FLI-1 is normally expressed in endothelial cells and in hematopoietic cells, including T lymphocytes. The immunohistochemical detection of FLI-1 protein has been shown in two recent studies to be valuable in the discrimination of ES/PNET from most of its potential mimics, with the notable exception of lymphoblastic lymphoma.
The FLI-1 gene has also recently been shown to play an important role in the embryologic development of blood vessels. Expression of FLI-1 protein in adult endothelial cells in all types of blood vessels (arterial, venous, and lymphatic) has previously been shown both in our previous work and in that of Nilsson et al.
Folpe et al. found FLI-1 to be a highly sensitive (92%) and, with regards to the cases evaluated in this study, specific (100%) marker of both benign and malignant vascular tumors. The “absolute specificity” of FLI-1 is of course lower, given its expression in ES/PNET and lymphomas. FLI-1 expression appears to be the first reliable nuclear marker of endothelial differentiation. In particular, Folpe et al. found that FLI-1 reliably distinguished epithelioid forms of angiosarcoma from two important mimics, epithelioid sarcoma and carcinoma.
Assoc. products: WT-1, CD99, Synaptophysin, Chromogranin A, CK AE1/AE3
The FLI-1 gene and FLI-1 protein are best known for their critical role in the pathogenesis of ES/PNET. More than 85% of ES/PNET are characterized by the translocation t(11;22)(q24;q12) that results in the fusion of the ews gene on chromosome 22 to the FLI-1 gene on chromosome 11. FLI-1 is a member of the ETS (erythroblastosis virus-associated transforming sequences) family of DNA-binding transcription factors and is involved in cellular proliferation and tumorigenesis. FLI-1 is normally expressed in endothelial cells and in hematopoietic cells, including T lymphocytes. The immunohistochemical detection of FLI-1 protein has been shown in two recent studies to be valuable in the discrimination of ES/PNET from most of its potential mimics, with the notable exception of lymphoblastic lymphoma.
The FLI-1 gene has also recently been shown to play an important role in the embryologic development of blood vessels. Expression of FLI-1 protein in adult endothelial cells in all types of blood vessels (arterial, venous, and lymphatic) has previously been shown both in our previous work and in that of Nilsson et al.
Folpe et al. found FLI-1 to be a highly sensitive (92%) and, with regards to the cases evaluated in this study, specific (100%) marker of both benign and malignant vascular tumors. The “absolute specificity” of FLI-1 is of course lower, given its expression in ES/PNET and lymphomas. FLI-1 expression appears to be the first reliable nuclear marker of endothelial differentiation. In particular, Folpe et al. found that FLI-1 reliably distinguished epithelioid forms of angiosarcoma from two important mimics, epithelioid sarcoma and carcinoma.
Assoc. products: WT-1, CD99, Synaptophysin, Chromogranin A, CK AE1/AE3
Quality
 IVD |  IVD |  IVD |  RUO |
Linkage
FLI-1 Positive Control Slides, Product No. 254S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Other Notes
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
control
Product No.
Description
Pricing
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
C Blind et al.
Journal of clinical pathology, 61(1), 79-83 (2007-04-07)
Archived tissue blocks preserve the antigenicity of samples for a long time under normal storage conditions, whereas tissue sections may show a diminished immunoreactivity over time. Little is known about the processes responsible for antigenicity loss and how tissue sections
Dale A Ellison et al.
Human pathology, 38(2), 205-211 (2006-12-01)
Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET) is a rare primary tumor of the kidney with morphologic features similar to those of other primitive tumors. Previous studies have shown that these tumors frequently stain positively with immunostains against CD99 and FLI-1
P Mhawech-Fauceglia et al.
Histopathology, 49(6), 569-575 (2006-12-14)
To compare the sensitivity and specificity of the recently commercially available FLI-1 monoclonal (FLI-1m) antibody with the currently used antibodies [CD99 and FLI-1 polyclonal (FLI-1p)] in the diagnosis of Ewing's sarcoma/primitive neuroectodermal tumour (EWS/PNET) and to determine the diagnostic value
Naoto Kuroda et al.
Medical molecular morphology, 39(4), 221-225 (2006-12-26)
A 29-year-old woman presented with facial edema, and imaging disclosed a tumor extending from the anterior chest wall to the anterosuperior aspect of the mediastinum. Transbronchial cytology of the primary tumor and biopsy of the metastatic scalp lesion were performed.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service